German company BAYER has hived off its biotech respiratory drug projects into a new company called AEROVANCE, funded to the tune of USD 32 billion by a group of investors led by APAX PARTNERS. BAYER will hold a 19.9% stake in AEROVANCE. AEROVANCE will hold the rights to two lead BAYER projects, for asthma and smoker's lung.